News Highlights

January 10, 2012
Maxygen Announces $10 Million Stock Repurchase Program

November 9, 2011
Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome

November 7, 2011
Maxygen Reports Third Quarter 2011 Financial Results

October 10, 2011
Maxygen Announces Final Rejection of All Claims of Amgen ‘804 Patent in Inter Partes Reexamination Proceeding

September 8, 2011
Maxygen Announces $10 Million Increase in Stock Repurchase Program